Option chain shows key data for OncoCyte's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OncoCyte.

OncoCyte (NASDAQ:OCX) Stock, Option Chain

OncoCyte

OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

ALLR

BPTS

MARPS

SINT

Shares of  Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Short Ideas

CRIS

RVMD

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q2

OncoCyte Corp

Press Releases

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Health Care

Oncocyte to Participate in "J.P. Morgan Week" and Host Investor Meetings

Biotech

General

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Management

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Prices $29.1 Million Equity Offering

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Veradigm Announces Board Expansion and Changes

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Earnings

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

MDRX

QSII

ZIMV

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Atossa Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

Climb Bio

Editas Medicine

EXoZymes

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Senti Biosciences

Tenaya Therapeutics

Vigil Neuroscience

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Exicure

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Lake Street

Stephens & Co.

Needham

Benchmark

Piper Sandler

Comments

OncoCyte

OncoCyte (OCX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga